These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. T Cell-Mediated Immune Responses to AAV and AAV Vectors. Ertl HCJ Front Immunol; 2021; 12():666666. PubMed ID: 33927727 [TBL] [Abstract][Full Text] [Related]
24. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Meliani A; Boisgerault F; Hardet R; Marmier S; Collaud F; Ronzitti G; Leborgne C; Costa Verdera H; Simon Sola M; Charles S; Vignaud A; van Wittenberghe L; Manni G; Christophe O; Fallarino F; Roy C; Michaud A; Ilyinskii P; Kishimoto TK; Mingozzi F Nat Commun; 2018 Oct; 9(1):4098. PubMed ID: 30291246 [TBL] [Abstract][Full Text] [Related]
25. Regulatory and Exhausted T Cell Responses to AAV Capsid. Gernoux G; Wilson JM; Mueller C Hum Gene Ther; 2017 Apr; 28(4):338-349. PubMed ID: 28323492 [TBL] [Abstract][Full Text] [Related]
26. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. Masat E; Pavani G; Mingozzi F Discov Med; 2013 Jun; 15(85):379-89. PubMed ID: 23819952 [TBL] [Abstract][Full Text] [Related]
27. AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye. Reichel FF; Dauletbekov DL; Klein R; Peters T; Ochakovski GA; Seitz IP; Wilhelm B; Ueffing M; Biel M; Wissinger B; Michalakis S; Bartz-Schmidt KU; Fischer MD; Mol Ther; 2017 Dec; 25(12):2648-2660. PubMed ID: 28970046 [TBL] [Abstract][Full Text] [Related]
28. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Mingozzi F; High KA Blood; 2013 Jul; 122(1):23-36. PubMed ID: 23596044 [TBL] [Abstract][Full Text] [Related]
29. Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial. Vandamme C; Adjali O; Mingozzi F Hum Gene Ther; 2017 Nov; 28(11):1061-1074. PubMed ID: 28835127 [TBL] [Abstract][Full Text] [Related]
30. Effect of CpG Depletion of Vector Genome on CD8 Bertolini TB; Shirley JL; Zolotukhin I; Li X; Kaisho T; Xiao W; Kumar SRP; Herzog RW Front Immunol; 2021; 12():672449. PubMed ID: 34135899 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays. Gorovits B; Azadeh M; Buchlis G; Harrison T; Havert M; Jawa V; Long B; McNally J; Milton M; Nelson R; O'Dell M; Richards K; Vettermann C; Wu B AAPS J; 2021 Sep; 23(6):108. PubMed ID: 34529177 [TBL] [Abstract][Full Text] [Related]
32. Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model. Wang Z; Halbert CL; Lee D; Butts T; Tapscott SJ; Storb R; Miller AD Gene Ther; 2014 Apr; 21(4):363-70. PubMed ID: 24500525 [TBL] [Abstract][Full Text] [Related]
37. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. Moskalenko M; Chen L; van Roey M; Donahue BA; Snyder RO; McArthur JG; Patel SD J Virol; 2000 Feb; 74(4):1761-6. PubMed ID: 10644347 [TBL] [Abstract][Full Text] [Related]
38. Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy. Ertl HCJ; High KA Hum Gene Ther; 2017 Apr; 28(4):328-337. PubMed ID: 28042943 [TBL] [Abstract][Full Text] [Related]
39. Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity. Rossi A; Dupaty L; Aillot L; Zhang L; Gallien C; Hallek M; Odenthal M; Adriouch S; Salvetti A; Büning H Sci Rep; 2019 Mar; 9(1):3631. PubMed ID: 30842485 [TBL] [Abstract][Full Text] [Related]
40. Answered and Unanswered Questions in Early-Stage Viral Vector Transduction Biology and Innate Primary Cell Toxicity for Dudek AM; Porteus MH Front Immunol; 2021; 12():660302. PubMed ID: 34122418 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]